| Primary |
| Multiple Myeloma |
47.3% |
| Drug Use For Unknown Indication |
25.3% |
| Product Used For Unknown Indication |
10.1% |
| Plasma Cell Myeloma |
5.6% |
| Myelodysplastic Syndrome |
1.9% |
| Myelofibrosis |
1.6% |
| Pain |
1.3% |
| Amyloidosis |
1.0% |
| Prophylaxis |
0.8% |
| Hypertension |
0.7% |
| Malignant Melanoma |
0.6% |
| Prostate Cancer |
0.6% |
| Nausea |
0.6% |
| Sarcoma |
0.5% |
| Brain Neoplasm Malignant |
0.4% |
| Glioblastoma Multiforme |
0.4% |
| Constipation |
0.3% |
| Non-small Cell Lung Cancer |
0.3% |
| Systemic Lupus Erythematosus |
0.3% |
| Mantle Cell Lymphoma |
0.3% |
|
| Death |
13.7% |
| Blood Human Chorionic Gonadotropin Increased |
12.2% |
| Multiple Myeloma |
10.3% |
| Pneumonia |
7.4% |
| Sepsis |
5.2% |
| Renal Failure |
4.9% |
| Thrombosis |
4.6% |
| Respiratory Failure |
4.5% |
| Neoplasm Progression |
4.3% |
| Neuropathy Peripheral |
4.2% |
| Vomiting |
3.9% |
| Pulmonary Embolism |
3.7% |
| Cardiac Disorder |
3.0% |
| Thrombocytopenia |
3.0% |
| Plasma Cell Myeloma |
2.7% |
| Disease Progression |
2.6% |
| Renal Disorder |
2.5% |
| Urinary Tract Infection |
2.5% |
| Renal Failure Chronic |
2.4% |
| Somnolence |
2.4% |
|
| Secondary |
| Drug Use For Unknown Indication |
34.6% |
| Multiple Myeloma |
31.2% |
| Product Used For Unknown Indication |
17.2% |
| Plasma Cell Myeloma |
5.5% |
| Pain |
2.0% |
| Nausea |
1.7% |
| Hypertension |
1.1% |
| Prophylaxis |
0.9% |
| Myelodysplastic Syndrome |
0.8% |
| Asthma |
0.8% |
| Lymphangioma |
0.7% |
| Diabetes Mellitus |
0.6% |
| Myelofibrosis |
0.5% |
| Constipation |
0.5% |
| Anaemia |
0.5% |
| Anxiety |
0.4% |
| Sarcoidosis |
0.3% |
| Systemic Lupus Erythematosus |
0.3% |
| Lepromatous Leprosy |
0.2% |
| Lichen Planus |
0.2% |
|
| Blood Human Chorionic Gonadotropin Increased |
20.9% |
| Multiple Myeloma |
12.6% |
| Death |
10.4% |
| Vomiting |
6.2% |
| Neuropathy Peripheral |
5.2% |
| Sepsis |
5.1% |
| Human Chorionic Gonadotropin Increased |
3.7% |
| Pneumonia |
3.7% |
| Blood Human Chorionic Gonadotropin Abnormal |
3.6% |
| Somnolence |
3.6% |
| White Blood Cell Count Decreased |
3.1% |
| Deep Vein Thrombosis |
2.8% |
| Acute Myeloid Leukaemia |
2.6% |
| Cardiac Disorder |
2.6% |
| Myelodysplastic Syndrome |
2.6% |
| Plasma Cell Myeloma |
2.5% |
| Pulmonary Embolism |
2.5% |
| Renal Failure |
2.3% |
| Fall |
2.0% |
| Thrombosis |
2.0% |
|
| Concomitant |
| Multiple Myeloma |
28.5% |
| Pain |
8.8% |
| Osteoporosis |
8.2% |
| Metastases To Bone |
6.8% |
| Nuclear Magnetic Resonance Imaging |
5.3% |
| Stem Cell Transplant |
4.5% |
| Hypercalcaemia |
4.1% |
| Plasma Cell Myeloma |
4.1% |
| Neoplasm Malignant |
3.8% |
| Bone Loss |
3.6% |
| Nuclear Magnetic Resonance Imaging Brain |
3.6% |
| Product Used For Unknown Indication |
2.6% |
| Anaemia |
2.4% |
| Bone Lesion |
2.4% |
| Oral Infection |
2.3% |
| Blood Pressure Management |
1.8% |
| Constipation |
1.8% |
| Diabetes Mellitus |
1.8% |
| Light Chain Analysis Increased |
1.8% |
| Myelodysplastic Syndrome |
1.8% |
|
| Weight Decreased |
22.5% |
| Tooth Extraction |
18.8% |
| Wound Drainage |
8.8% |
| Renal Failure Acute |
6.3% |
| Weight Increased |
5.0% |
| Wheezing |
3.8% |
| Visual Acuity Reduced |
3.1% |
| White Blood Cell Count Decreased |
3.1% |
| Acute Myeloid Leukaemia |
2.5% |
| Nephrogenic Systemic Fibrosis |
2.5% |
| Skin Tightness |
2.5% |
| Upper Respiratory Tract Infection |
2.5% |
| Urinary Incontinence |
2.5% |
| Urticaria |
2.5% |
| Venous Thrombosis |
2.5% |
| Vertigo |
2.5% |
| Vision Blurred |
2.5% |
| Wound Treatment |
2.5% |
| Pneumonia |
1.9% |
| Rash |
1.9% |
|
